Seer Reports First Quarter 2022 Financial Results
Demonstrated solid commercial traction with continued robust interest in the Proteograph Product Suite
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2022.
“We had a strong start to the year as we further ramped our commercial efforts, expanded our installed base, and made tangible progress against our strategic plan. I am thrilled to see the growing impact of our unique technology in enabling researchers to interrogate the proteome deeply, at scale and without limitations to prescribed targets,” said Omid Farokhzad, Chief Executive Officer and Chair, “As our customers deepen their experience with the Proteograph Product Suite, the data they produce will be key to accelerating adoption and establishing a rich pipeline of potential customers. We look forward to updating you on their progress throughout the year.”
- Revenue of $3.3 million for the first quarter 2022
- Delivered the first Proteograph Product Suite orders as part of Broad Commercial release across multiple geographies, including North America, Europe and Asia
- Announced the publication of a seminal study in the Proceedings of the National Academy of Sciences (PNAS) demonstrating performance of the Proteograph Product Suite for deep, unbiased, precise, scalable proteomics
- Hired Scott Thomas as Chief Commercial Officer
First Quarter 2022 Financial Results
Revenue was $3.3 million for the three months ended March 31, 2022, as compared to $62 thousand for the three months ended March 31, 2021. The increase was primarily due to an increase in sales of products related to the Proteograph Product Suite. Product-related revenue for the first quarter of 2022 was $3.2 million, including $1.1 million of related party revenue, and consisted of sales of SP100 instruments, consumable kits and platform evaluations.
Gross profit, inclusive of grant and other revenue, was $1.2 million and gross margin was 38% for the first quarter of 2022.
Operating expenses were $25.0 million for the first quarter of 2022, including $8.1 million of stock based compensation, as compared to $16.6 million, including $6.0 million of stock based compensation, for the corresponding prior year period. The increase in expenses was driven by increased employee compensation and other related expenses, including stock-based compensation, and increased expenses related to the expansion of our facilities and other costs related to being a publicly traded company.
Net loss was $23.6 million for the first quarter of 2022, as compared to $16.4 million for the corresponding prior year period.
Cash, cash equivalents and investments were approximately $472 million as of March 31, 2022.
Seer continues to expect full year 2022 revenue to be in the range of $14.0 million to $16.0 million, and, as previously disclosed, Seer also expects to continue to increase investments in its commercial, operations, research and development activities to drive long-term growth and value creation.
Seer will host a conference call to discuss the first quarter financial results on Wednesday, May 4, 2022 at 2:00 pm Pacific Time / 5:00 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company’s current views with respect to certain current and future events and financial performance. Words such as “expects,” “anticipates,” “projects,” “intends,” “plans,” “believes,” “estimates,” variations of such words, and similar expressions are also intended to identify such forward-looking statements. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding the Company’s outlook for fiscal year 2022. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Quarterly Report on Form 10-Q, to be filed with the SEC, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
|Three Months Ended March 31,|
|Grant and other||14||62|
|Cost of revenue:|
|Total cost of revenue||2,068||—|
|Research and development||10,732||6,227|
|Selling, general and administrative||14,298||10,333|
|Total operating expenses||25,030||16,560|
|Loss from operations||(23,786||)||(16,498||)|
|Other income (expense):|
|Total other income||140||69|
|Other comprehensive loss:|
|Unrealized loss on available-for-sale securities||(1,691||)||(26||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.38||)||$||(0.27||)|
|Weighted-average common shares outstanding, basic and diluted||62,003,504||59,887,842|
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
|March 31,||December 31,|
|Cash and cash equivalents||$||225,334||$||232,813|
|Accounts receivable, net||2,793||2,495|
|Related party receivables||1,126||1,283|
|Prepaid expenses and other current assets||4,221||3,336|
|Total current assets||457,456||411,699|
|Operating lease right-of-use assets||28,411||20,142|
|Property and equipment, net||13,654||13,087|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Operating lease liabilities, current||1,090||864|
|Total current liabilities||11,152||13,423|
|Operating lease liabilities, net of current portion||29,134||22,459|
|Other noncurrent liabilities||341||341|
|Commitments and contingencies|
|Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of March |
31, 2022 and December 31, 2021; zero shares issued and outstanding as of
March 31, 2022 and December 31, 2021
|Class A common stock, $0.00001 par value; 94,000,000 shares authorized as |
of March 31, 2022 and December 31, 2021; 58,237,703 and 57,493,005 shares
issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
| Class B common stock, $0.00001 par value; 6,000,000 shares authorized as |
of March 31, 2022 and December 31, 2021; 4,055,190 and 4,522,478 shares
issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
|Additional paid-in capital||638,860||629,981|
|Accumulated other comprehensive loss||(2,227||)||(536||)|
|Total stockholders’ equity||486,458||502,916|
|Total liabilities and stockholders’ equity||$||527,085||$||539,139|